Through 96 weeks, no patient experienced virologic breakthrough due to entecavir resistance. Cumulative confirmed HBeAg seroconversion occurred in 31% of entecavir-treated versus 25% of lamivudine-treated patients (P = NS). 0001) and ALT normalization (87% vs 79% P =. Higher proportions of entecavir-treated than lamivudine-treated patients achieved cumulative confirmed HBV DNA <300 copies/mL by PCR (80% vs 39% P <. Similar proportions of entecavir-treated and lamivudine-treated patients achieved HBeAg seroconversion (11% vs 12%, respectively). Cumulative confirmed proportions of all treated patients who achieved these responses were also analyzed.Īmong patients treated in year 2, 74% of entecavir-treated versus 37% of lamivudine-treated patients achieved HBV DNA <300 copies/mL by polymerase chain reaction (PCR), and 79% of entecavir-treated versus 68% of lamivudine-treated patients normalized ALT levels. Patients continuing in year 2 (entecavir, n = 243 lamivudine, n = 164) were assessed for serum hepatitis B virus (HBV) DNA, alanine aminotransferase (ALT) normalization, HBeAg seroconversion, and safety.
At week 52, protocol-defined virologic responders could continue blinded treatment for up to 96 weeks. We evaluated continued entecavir and lamivudine treatment through 96 weeks.ħ09 HBeAg-positive CHB patients were randomized to entecavir 0.5 mg (n = 354) or lamivudine 100 mg (n = 355) once daily. puma proadapt mid golf shoes clan invasion record sheets catawba county health department covid test.
Entecavir demonstrated superior benefit to lamivudine at 48 weeks in nucleoside-naive patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB).
0 kommentar(er)
